Navigation Links
Molecule Nutlin-3a activates a signal inducing cell death and senescence in primary brain tumors
Date:4/20/2011

Researchers of Apoptosis and Cancer Group of the Bellvitge Biomedical Research Institute (IDIBELL) have found that a small molecule, Nutlin-3a, an antagonist of MDM2 protein, stimulates the signalling pathway of another protein, p53. By this way, it induces cell death and senescence (loss of proliferative capacity) in brain cancer, a fact that slows its growth. These results open the door for MDM2 agonists as new treatments for glioblastomas. The study has been published at the journal PLoS ONE.

Glioblastoma multiforme is the most common brain tumour in adults and the most aggressive. Despite efforts on new treatments and technological innovation in neurosurgery, radiation therapy and clinical trials of new therapeutic agents, most patients die two years after diagnosis. Avelina Tortosa, IDIBELL and University of Barcelona (UB) researcher, coordinator of the study, explained that one objective of her group is "to find substances that sensitize tumour cells to radiotherapy for more efficient treatments".

New therapeutic targets

There is evidence that several genetic alterations promote the growth, invasion and resistance to stimuli that induce programmed cell death (apoptosis). In this sense, the pilot project TCGA (The Cancer Genome Atlas) has sequenced the genome of up to 25 glioblastomas noting that 14% of patients have an increased expression of MDM2 and 35% had alterations in p53 expression (apoptosis-inducing). That is why research is now focused on the development of new therapeutic strategies that target the apoptosis in gliomas.

The aim of this study was to investigate the antitumor activity of Nutlin-3a in cell lines and primary cultures of glioblastoma. Researchers have shown that Nutlin-3a induces apoptosis and cellular senescence by stimulating the p53 pathway in cells, because cells with mutations in this protein don't produce this response. They have also discovered that the use of Nutlin-3a enhances the response of glioblastoma cells to radiotherapy. "The radiation induced DNA damage of tumour cells", explained Tortosa, "the cells activate repairing mechanisms and, if they are unable to repair, they destruct themselves (a mechanism known as apoptosis). With Nutlin-3a we have seen that increases tumour cell death and therefore increases the effectiveness of radiotherapy treatment. "

In conclusion, the results suggest that the MDM2 antagonists may be new therapeutic options for the treatment of glioblastoma patients.


'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Related medicine news :

1. Small molecules inhibit growth of human tumor cells
2. Molecules identified that help propel cancer metastasis
3. Scientists identify molecule that can increase blood flow in vascular disease
4. New role for an old molecule: protecting the brain from epileptic seizures
5. Study Links Brain Molecule to Risk of Major Depression
6. Membrane molecule keeps nerve impulses hopping
7. Researchers reveal function of novel molecule that underlies human deafness
8. Small molecules may prevent ebola infection
9. Molecules made by IUPUI students may have potential to cure diseases
10. Link between signaling molecules could point way to therapies for epilepsy, stroke, other diseases
11. Structure of key molecule in immune system provides clues for designing drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: